Cell and Gene therapy from China is cheap because all the COGS are lower. COGS, research and studies are planned for affordability right at the beginning. However, cheap does not mean that the quality is bad. However, the cost is not very very low because the companies need to move to profitability too. In China the total cost $50k /year is the total that is reimbursable for treatment. Another advantage is that they are setting up everything new so it is also an advantage of second mover with specific purpose built tools, processes, and plans. Chinese companies do want to be global and so are planning development that is fast, their results are published and they are seeking collaborations. The ecosystem also makes it available for internal companies but also global companies.
Some leaders in the field that have expressed their opinion on Endpoints day
Xiao Xioa – Belief Biomed Inc
Emma Wang – CDO/CTA YolTech Therapeutics
Zhenhua Wu – Exegenesis Bio
Lijun Wang – Cojourney
